INC Research Expands South Korean Presence with New Office

Raleigh, N.C., Sept. 12, 2012 - INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced the opening of a facility in South Korea to manage the growing demand for world-class clinical development programs. Located in the heart of Seoul's business district, the Company's South Korean team is primarily focused on study start-up and clinical operations activities around key therapeutic areas.

"The South Korean government has renewed its focus on healthcare and clinical development leading to a dramatic increase in the opportunities for biopharmaceutical companies' drug development programs," said Kelvin Logan, PhD, President, Asia/Pacific. "Our expanded team is equipped to help customers take advantage of the benefits of conducting clinical trials in this region, while navigating through the developing regulatory environment and leveraging support resources."

South Korea has made major progress in establishing centers of excellence and state-of-the-art facilities for clinical trials, and has developed a transparent and well-organized regulatory infrastructure for clear approval pathways. To ensure smooth study start-up and successful management of trials, INC Research's local team has formed relationships with regional key opinion leaders, accredited KFDA investigative sites and clinical trial center support programs through organizations such as KoNECT, the South Korea National Enterprise for Clinical Trials.

The new office is located in Gangnam-gu, Seoul, in the central business district with easy access to client and business partners and will be managed by Dr. Jessica Liu, General Manager and Lee Sun-Mee, Associate Director of Clinical Operations and Site Head for South Korea.

INC Research provides Phase I to IV clinical development services in the Asia/Pacific region with extensive coverage across China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand and New Zealand. The Company has the broad regional presence, therapeutic expertise, operational excellence and ability to apply international insights to local projects to meet the needs of drug developers. For more information, visit the site for more facts on INC Research's clinical trial services and experience in the region.

About INC Research, LLC
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areasand innovative pediatric and women's health trials. The Company's Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit or follow us at @inc_research.

Contact: Lori Dorer, Media (513) 345-1685

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.